36 results
8-K
EX-10.1
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
involving any kind of hazardous, toxic or other wastes, pollutants, contaminants, petroleum products or other hazardous or toxic substances, chemicals
8-K
EX-10.1
IKT
Inhibikase Therapeutics Inc
1 Feb 24
Entry into a Material Definitive Agreement
4:09pm
, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating
424B3
mkx bi0bs
4 Apr 23
Prospectus supplement
4:57pm
POS AM
nofmx3tt vl05
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
8-K
EX-99.1
qml9lfvbjq mr4opa
16 Sep 22
Regulation FD Disclosure
4:09pm
8-K
EX-10.1
of3l5dsf
16 May 22
Entry into a Material Definitive Agreement
9:49pm
8-K
EX-99.1
x3q 1a32fwgzo
21 Apr 22
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
n1o4etcmemp4dy4g
20 Jan 22
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT
4:10pm
8-K
EX-99.1
xmn6qalugcid1 xu7
19 Oct 21
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT
5:03pm
8-K
EX-99.1
zg6bmr5qbtzw5z9
17 Aug 21
Regulation FD Disclosure
5:02pm
424B4
k0jz3hpnhayi
17 Jun 21
Prospectus supplement with pricing info
4:31pm
8-K
EX-1.1
4eajha5h
16 Jun 21
Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock
9:20am